1374639-79-8

Basic information

• Product Name: LEE011 (succinate hydrate)
• Synonyms: LEE011 (succinate hydrate);Ribociclib (succinate hydrate);Ribociclib Succinate hydrat;Ribociclib (LEE011) succinate hydrate
• CAS NO: 1374639-79-8
• Molecular Formula: C27H36N8O5
• Molecular Weight: 552.64
• Mol File: 1374639-79-8.mol
• Article Data: 0

Chemical Properties

• Appearance: /
• CAS DataBase Reference: LEE011 (succinate hydrate)(CAS DataBase Reference)
• NIST Chemistry Reference: LEE011 (succinate hydrate)(1374639-79-8)
• EPA Substance Registry System: LEE011 (succinate hydrate)(1374639-79-8)

Safety Data

• Hazardous Substances Data: 1374639-79-8(Hazardous Substances Data)

Usage

Description

LEE011 (succinate hydrate) is a cyclin-dependent kinase (CDK) inhibitor, a chemical compound that plays a crucial role in the regulation of cell cycle progression. It is specifically designed to target and inhibit the activity of CDK4 and CDK6 enzymes, which are key regulators in cell cycle control. By blocking these enzymes, LEE011 can effectively slow down the growth and division of cancer cells, making it a promising therapeutic agent for the treatment of advanced or metastatic breast cancer.

Uses

Used in Pharmaceutical Industry:
LEE011 (succinate hydrate) is used as an anticancer agent for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. Its mechanism of action involves the specific inhibition of CDK4 and CDK6 enzymes, which are essential for cell cycle progression. By targeting these enzymes, LEE011 can effectively suppress tumor growth and improve patient outcomes.
In addition to its primary use in cancer treatment, LEE011 (succinate hydrate) may also have potential applications in other areas of pharmaceutical research and development. Its ability to regulate cell cycle progression could make it a valuable tool for studying the underlying mechanisms of various diseases and conditions, as well as for developing new therapeutic strategies to combat them. However, further research and clinical trials are needed to fully explore and validate these potential applications.